Dowling & Yahnke LLC lowered its stake in shares of Colgate-Palmolive (NYSE:CL) by 9.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,875 shares of the company’s stock after selling 6,984 shares during the quarter. Dowling & Yahnke LLC’s holdings in Colgate-Palmolive were worth $5,163,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Jacobi Capital Management LLC boosted its holdings in shares of Colgate-Palmolive by 125.5% in the 3rd quarter. Jacobi Capital Management LLC now owns 1,443 shares of the company’s stock valued at $104,000 after purchasing an additional 803 shares in the last quarter. Krilogy Financial LLC lifted its stake in shares of Colgate-Palmolive by 23.0% in the 2nd quarter. Krilogy Financial LLC now owns 1,547 shares of the company’s stock valued at $115,000 after acquiring an additional 289 shares during the last quarter. Harbour Capital Advisors LLC bought a new position in shares of Colgate-Palmolive in the 1st quarter valued at $121,000. Hanson & Doremus Investment Management lifted its stake in shares of Colgate-Palmolive by 4.5% in the 2nd quarter. Hanson & Doremus Investment Management now owns 1,630 shares of the company’s stock valued at $121,000 after acquiring an additional 70 shares during the last quarter. Finally, Captrust Financial Advisors bought a new position in shares of Colgate-Palmolive in the 2nd quarter valued at $122,000. 72.85% of the stock is currently owned by institutional investors and hedge funds.
Colgate-Palmolive (CL) traded down $3.75 during mid-day trading on Friday, reaching $73.56. The company’s stock had a trading volume of 12,126,074 shares, compared to its average volume of 3,340,000. The firm has a market cap of $64,590.00, a P/E ratio of 32.26, a P/E/G ratio of 3.21 and a beta of 0.81. The company has a debt-to-equity ratio of 24.42, a current ratio of 1.23 and a quick ratio of 0.92. Colgate-Palmolive has a fifty-two week low of $63.43 and a fifty-two week high of $77.91.
Colgate-Palmolive (NYSE:CL) last released its quarterly earnings results on Friday, January 26th. The company reported $0.75 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.75. The business had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.92 billion. Colgate-Palmolive had a return on equity of 2,782.56% and a net margin of 15.10%. The company’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.75 EPS. equities research analysts expect that Colgate-Palmolive will post 2.87 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Tuesday, January 23rd will be paid a $0.40 dividend. The ex-dividend date is Monday, January 22nd. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.18%. Colgate-Palmolive’s payout ratio is presently 70.18%.
A number of research analysts have recently commented on the company. Zacks Investment Research cut Colgate-Palmolive from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. KeyCorp reaffirmed a “hold” rating on shares of Colgate-Palmolive in a research report on Monday, October 16th. Macquarie raised Colgate-Palmolive from a “neutral” rating to an “outperform” rating and set a $81.00 target price for the company in a research report on Tuesday, December 19th. Deutsche Bank assumed coverage on Colgate-Palmolive in a research report on Wednesday, December 13th. They set a “hold” rating and a $75.00 target price for the company. Finally, Jefferies Group reaffirmed a “hold” rating and set a $79.00 target price on shares of Colgate-Palmolive in a research report on Friday. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $77.17.
In other news, Director Stephen I. Sadove sold 20,780 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $70.52, for a total value of $1,465,405.60. Following the transaction, the director now owns 36,268 shares in the company, valued at approximately $2,557,619.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Justin Skala sold 126,393 shares of the business’s stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $72.97, for a total value of $9,222,897.21. Following the completion of the transaction, the chief operating officer now owns 262,361 shares in the company, valued at approximately $19,144,482.17. The disclosure for this sale can be found here. Insiders sold a total of 181,950 shares of company stock worth $13,237,385 in the last 90 days. Company insiders own 1.02% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/28/colgate-palmolive-cl-position-reduced-by-dowling-yahnke-llc.html.
Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.